James D. Douketis

Perioperative Management of Patients on Factor XI or Factor XIa Inhibitors.

Periprocedural data from completed Phase 2 clinical trials demonstrate that for primary venous thromboprophylaxis of patients undergoing major orthopedic surgery who are at risk of major bleeding, strategies to inhibit FXI result in a lower risk of venous thromboembolism and lower clinically relevant bleeding compared...